How would you manage a male patient who has a germline BRCA2 mutation with node-positive, HR-positive invasive ductal carcinoma who is unable/unwilling to receive tamoxifen or AI + goserelin?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Ohio State University • HR+ • NCI-CCC Breast Tumor Board Question • BRCA+ • Breast Cancer, Non-metastatic • Male Breast Cancer

Is there a role for raloxifene, PARP inhibition, or CDK4/6 inhibition? If so, how would you sequence?

Patient has RS 22, G2, < 3 LN positive after mastectomy and ALND; declined chemotherapy.

Also in year 3 of remission from pancreatic cancer s/p gem/nab-paclitaxel

Related Questions